ArticleEuropean journal of immunology2026
Accumulation of Siglec10
Article in European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Glioblastoma (GBM) is one of the most aggressive primary brain tumors in adults. Despite various strategies, including differential single-cell gene expression analyses between GBM and healthy tissues, none of the resulting findings could benefit the development of promising therapies, yet. Various macrophage populations coevolve in the tumor microenvironment of GBMs and not only support tumor immune evasion but also tumor spreading throughout the surrounding tissue. To distillate unique immune cell features of GBMs, we compared their immune cell composition with other central nervous system (CNS) tumor entities, in particular meningiomas (MNGs), non-GBM gliomas, and metastases (MTS). We could identify a macrophage population characterized by the coexpression of CX3CR1 and Siglec10, representing a potential indicator population of GBMs. This GBM-specific macrophage subset might be supported by a glioma-characteristic lipid mediator (LM) milieu of enriched docosahexaenoic acid (DHA) and its lipoxygenase (LOX)-derived metabolites. Moreover, the GBM tumor microenvironment (TME) is enriched in arachidonic acid (AA)-derived cyclooxygenase (COX) products prostaglandins (PG) E
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.